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OBJECTIVES This study sought to evaluate what set of factors correlate with higher or lower C-reactive
protein (CRP) levels in patients receiving standard and intensive statin therapy.
BACKGROUND C-reactive protein levels in blood are becoming recognized as a potential means of monitoring
cardiovascular risk. Although statin therapy is known to reduce CRP levels, many patients
have a high CRP level despite statin therapy.
METHODS This study was a cross-sectional study of 2,885 patients from the Pravastatin or Atorvastatin
Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 (PROVE
IT-TIMI 22) trial, which assessed the relationship between uncontrolled cardiovascular risk
factors and CRP level at four months after enrollment.
RESULTS In a multivariate model, several risk factors were weakly but independently associated with
higher CRP levels: age, gender (with or without hormone replacement therapy), body mass
index 25 kg/m2, smoking, low-density lipoprotein 70 mg/dl, glucose 110 mg/dl,
high-density lipoprotein 50 mg/dl, triglycerides 150 mg/dl, and the intensity of statin
therapy. A direct relationship between the number of uncontrolled risk factors present and
CRP levels (p  0.0001) was observed for both statin regimens. Despite the presence of each
uncontrolled risk factor, prior randomization to intensive statin therapy was associated with
a lower CRP level (p  0.0001). Across all strata, defined by the number of uncontrolled risk
factors present, CRP levels were lower among those receiving intensive statin therapy.
CONCLUSIONS The use of intensive statin therapy lead to a lower CRP level independent of the presence of
single or multiple cardiovascular risk factors. Even among patients receiving intensive statin
therapy, a lower CRP level was observed in patients with the fewest coronary risk factors
present, suggesting that control of multiple risk factors may be a means to further achieve
lower CRP levels. (J Am Coll Cardiol 2005;46:1417–24) © 2005 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.024of Cardiology Foundation
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pnflammation, and C-reactive protein (CRP) in particular,
s an independent predictor of cardiovascular risk for the
evelopment of both coronary artery disease (CAD) in the
ealthy population (1) and recurrent events in patients with
nown CAD (2). It has also recently been observed that
chieving a lower CRP level with statin therapy is associated
ith a lower risk of recurrent events in patients with acute
oronary syndromes (ACS) (3), even after adjusting for all
ramingham risk factors and prior revascularization (4).
urther, greater reductions in CRP with statin therapy have
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ardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. The
ROVE IT-TIMI 22 study was funded by Bristol-Myers Squibb and Sankyo. Dr.
ay is funded by a British Heart Foundation International Fellowship.f
Manuscript received July 21, 2005; revised manuscript received August 3, 2005,
ccepted August 8, 2005.een associated with less progression of atherosclerosis in
atients with stable CAD (5).
However, despite statin therapy, many patients with
AD have a high CRP level (6), and an important clinical
uestion that has arisen is what else might be done to
urther lower CRP among patients receiving statin therapy.
e sought to identify the factors correlated with higher
RP levels among patients receiving two different statin
egimens to identify the future targets for intervention that
ight further lower CRP levels. First, we hypothesized that
he presence of cardiovascular risk factors (e.g., high body
ass index [BMI], low high-density lipoprotein [HDL]
evels) would be associated with differences in CRP levels
ven among patients receiving intensive therapy, and
econd, that intensive statin therapy would be an inde-
endent predictor of a lower CRP irrespective of risk
actor burden.
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atient population. The design of the Pravastatin or
torvastatin Evaluation and Infection Therapy–
hrombolysis In Myocardial Infarction 22 (PROVE IT-
IMI 22) protocol has been previously described (7).
riefly, 4,162 patients who had a total cholesterol level of
240 mg/dl and who had been hospitalized for an ACS
ithin the previous 10 days were enrolled. Eligible patients
ere randomly assigned to pravastatin 40 mg (standard
herapy) or atorvastatin 80 mg daily (intensive therapy), and
atifloxacin versus placebo, in a 2  2 factorial design.
ecause levels of metabolic markers and CRP during ACS
ay not reflect a true baseline, we used a cross-sectional
tudy design and included only patients in whom CRP, lipid
omponent, and glucose measurements were available at
our months (n 2,885) for this analysis. The analyses were
erformed at four months to allow full stabilization of CRP
evels, lipids, and glucose after ACS (3,7).
easurement of variables. Low-density lipoprotein
LDL), HDL, triglycerides (TG), glucose, and high sensi-
ivity CRP (hs-CRP) were measured in fasting samples in
he core laboratories (7). Total cholesterol, HDL, and TG
ere measured using an enzymatic colorimetric method
sing the Roche Modular system (LabCorp, Raritan, New
ersey). The LDL level was obtained by calculation (total
holesterol  [TG/5  HDL]). The CRP level was
easured using the validated Denka Seiken assay for hs-
RP (N.R., Children’s Hospital, Boston, Massachusetts).
lood pressure (BP), weight, and current medication use
ere recorded at each visit, and height and smoking status
ere measured at enrollment.
tatistical analysis. The CRP levels were not normally
istributed, and therefore are reported as median and
nterquartile range (IQR), and groups were compared using
he Wilcoxon rank sum test; CRP was subsequently log
ransformed at the model fitting stage. Other continuous
ariables were compared using t tests, and categorical
ariables were compared using chi-squared tests. An F test
Abbreviations and Acronyms
ACS  acute coronary syndrome
BMI  body mass index
BP  blood pressure
CAD  coronary artery disease
CI  confidence interval
CRP  C-reactive protein
HDL  high-density lipoprotein
hs-CRP  high-sensitivity CRP
IQR  interquartile range
LDL  low-density lipoprotein
PROVE IT–TIMI 22  Pravastatin or Atorvastatin
Evaluation and Infection
Therapy-Thrombolysis In
Myocardial Infarction 22
TG  triglycerideas used to test for the presence of interactions between setabolic factors (grouped by quartiles) in a linear regres-
ion model for log CRP.
Initial analyses combined the two statin arms to assess the
istribution of CRP as a function of potential risk factors.
he on-treatment uncontrolled risk factors at four months
ere defined as BMI 25 kg/m2 (World Health Organi-
ation cut off for overweight), BP130/85 mm Hg, glucose
110 mg/dl, TG 150 mg/dl (Adult Treatment Panel
ATP] III cut offs), and HDL 50 mg/dl. The presence of
linear correlation between log CRP and each risk factor
as assessed using the Pearson product moment correlation
oefficient, and the two statin treatments were compared
sing the Fisher z test. Relationships between log CRP and
range of metabolic factors were assessed for non-linearity
nd are graphically represented by fitting a robust local
egression model (Loess plot) (8).
The relationship between incremental risk factor burden
number of uncontrolled risk factors present) and CRP level
as determined for each statin regimen, and differences in
RP level across multiple groups were assessed using a
ruskal-Wallis test. Finally, linear regression analysis was
sed to identify predictors of log CRP in a multivariate
odel. The statistical analyses were performed by the TIMI
tudy group and the Nottingham Clinical Research group.
ESULTS
haracteristics at baseline and at four months. There
ere 2,885 patients on the study drug in whom metabolic
arkers and CRP measurements were available at four
onths (69% of the initial study cohort). The analysis
ohort of 2,885 patients did not differ significantly from the
,277 excluded patients in terms of age, gender, BMI, or
istory of diabetes, hypertension, or smoking. There were
o significant differences in baseline characteristics between
reatment strategies (Table 1). However, at four months,
ntensive statin therapy was associated with a lower LDL (p
0.0001), TG (p 0.0001), CRP (p 0.0001), and HDL
p  0.002) compared with standard therapy.
elationship between uncontrolled risk factors and CRP
evel. The relationship between month 4 CRP level (log
ransformed) and a number of variables of interest was
ssessed initially among all patients. The following correla-
ion coefficients were significantly different from zero: age (r
0.056), BMI (r  0.19), on treatment systolic blood
ressure (r  0.085), glucose (r  0.098), HDL (r 
0.056), LDL (r  0.17), and TG (r  0.12), but all
orrelations were weak. A graphical representation of the
omplex and varied relationship between log CRP and each
etabolic risk factor is shown in Figures 1A to 1F using a
oess plot.
Current smoking, diabetes, and the presence of uncon-
rolled metabolic risk factors at month 4 (specifically BP
130/85 mm Hg, fasting glucose 110 mg/dl, TG 150
g/dl, and BMI 25 kg/m2) were each associated with aignificantly higher CRP level compared with the absence of
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October 18, 2005:1417–24 CRP, Risk Factors, and Intensive Statin Therapyhe relevant risk factor, when both statin arms were com-
ined (Table 2, part A). Considering subgroups defined by
he presence of individual uncontrolled risk factors, use of
ntensive statin therapy was associated with a significantly
ower CRP compared with standard therapy (p  0.0001 in
he presence of each uncontrolled metabolic or lifestyle risk
actor) (Table 2, part B). Of the candidate variables studied
n univariate analyses, female gender was associated with the
ighest CRP level, especially when combined with hormone
eplacement therapy (Table 2, part A). Irrespective of
ormone replacement therapy use, women receiving inten-
ive therapy had significantly lower CRP levels (Table 2,
art B).
orrelations of lipid levels and CRP level. The relation-
hip between CRP level and the lipid parameters was also
ssessed for each statin regimen. Weak but significant
orrelations were observed between CRP (log transformed)
nd LDL among patients receiving pravastatin 40 mg or
torvastatin 80 mg (r  0.04 and r  0.15, respectively),
lthough these correlation coefficients were significantly
ifferent (Fisher z test, p  0.002). Similarly weak but
ignificant correlations were seen between CRP and TG (r
0.08 for pravastatin 40 mg, r  0.12 for atorvastatin 80
g) and between CRP and HDL (r  0.07 for both
tatin regimens); however, no significant differences in these
oefficients were observed between regimens (Fisher z test).
ith an apparent interaction between the statin regimen,
DL, and CRP, the relationships between CRP (log scale)
nd LDL were graphically reflected using a Loess plot for
able 1. Patient Characteristics at Baseline and Month 4 by Stat
Characteristics
aseline
Age, yrs (mean  SD)
Male (%)
Diabetes (%)
Smoking current (%)
Smoking past (%)
Hypertension (%)
Extent of disease 2 vessels with 50% stenosis (%)
BMI, kg/m2 (mean  SD)
onth 4
Beta-blockers (%)
ACE inhibitors (%)
Aspirin (%)
Clopidogrel (%)
Insulin (%)
Oral hypoglycemics (%)
HRT (% of females)
Systolic BP, mm Hg (mean  SD)
Diastolic BP, mm Hg (mean  SD)
LDL, mg/dl (mean  SD)
HDL, mg/dl (mean  SD)
Triglycerides, mg/dl (mean  SD)
Glucose, mg/dl (mean  SD)
CRP, mg/l (median and interquartile range)
CE  angiotensin-converting enzyme; BMI  body mass index; BP  blood pr
eplacement therapy; LDL  low-density lipoprotein.ach statin regimen (Fig. 2). hultivariate analysis. In a multivariate model for log CRP
hat included age, gender, lifestyle factors, metabolic abnor-
alities, and treatments potentially associated with differ-
nces in CRP, several variables were seen to have a signif-
cant correlation with CRP level (Table 3). In this
opulation in which everyone received a statin, prior ran-
omization to atorvastatin 80 mg was associated with a 27%
ower CRP compared with pravastatin 40 mg (95% confi-
ence interval [CI], 20 to 34; p  0.0001) independently of
DL, TG, and HDL levels. Beyond intensity of statin
herapy, a number of metabolic and lifestyle risk factors
ere also associated with higher CRP levels, in particular
moking (45% higher; 95% CI, 32 to 59) and BMI 25
42% higher; 95% CI, 27 to 58), p  0.0001 for each.
ignificant but weak correlations between age and CRP
evel were also observed, with an average CRP level that was
.2% higher per year (95% CI, 0.8 to 1.6, p  0.0001).
emale patients not receiving hormone replacement therapy
in the four months after ACS) had CRP levels 47% higher
han male patients (95% CI, 31 to 65), whereas those that
id take hormone replacement therapy were much higher
137% compared with male patients; 95% CI, 97 to 285),
oth p 0.0001. Both glucose and lipid abnormalities, such
s LDL 70 mg/dl, TG 150 mg/dl, and HDL 50
g/dl, were each associated with higher average CRP levels
by 19%, 20%, 15%, and 23%, respectively). A clinical event
etween enrollment and month 4 was associated with a 35%
igher CRP level (95% CI, 11 to 65; p  0.003), whereas
erapy
ard Therapy
 1,432)
Intensive Therapy
(n  1,453) p
.3  11.1 58.1  10.8 0.63
79.6 78.2 0.34
18 18.5 0.73
35.8 34.5 0.50
38.5 38.9 0.85
49.7 50.6 0.62
42.7 42.5 0.92
.6  5.6 29.6  5.7 0.98
83.7 83.8 0.90
61.5 58.8 0.14
95.5 94.5 0.23
30.2 32.3 0.21
4.7 4.8 0.86
13.8 12.2 0.19
28.1 26.2 0.60
.2  18 126  17.7 0.09
.9  10.3 75.5  10.4 0.40
.6  28.5 66.8  26.3 0.0001
4  12 42.6  11.4 0.002
.8  131.9 136.2  84.3 0.0001
.5  40.9 113.5  44.6 0.06
1 (1.0–4.5) 1.29 (0.6–2.9) 0.0001
; CRP  C-reactive protein; HDL  high-density lipoprotein; HRT  hormonein Th
Stand
(n
58
29
127
75
98
4
175
110
2.1igh blood pressure and diabetes or treatments such as
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CRP, Risk Factors, and Intensive Statin Therapy October 18, 2005:1417–24spirin, angiotensin-converting enzyme inhibitors, clopi-
ogrel, and gatifloxacin were not significantly related to
RP level in this model.
nteraction between metabolic risk factors and CRP
evel. Potential interactions between metabolic risk factors
nd CRP level were assessed in patients receiving atorva-
tatin 80 mg. Stratifying by LDL and glucose quartiles at
igure 1. The correlation between median C-reactive protein (CRP) level
isk factors (x axis) is shown for the whole cohort using a Loess plot: (
igh-density lipoprotein (HDL) (mg/dl), (D) versus body mass index (BMI
mm Hg). ATP  Adult Treatment Panel; WHO  World Health Org
able 2. The Relationship Between CRP at 4 Months and Indiv
RP By Statin Therapy in Subjects With Individual Risk Factor
(A)
Risk Factor
Present
ge 65 yrs 1.71 (0.8–3.9)
urrent smoker 2.06 (1.0–4.5)
iabetes 1.94 (0.9–4.5)
emales not on HRT 2.41 (1.1–5.3)
emales on HRT 3.70 (1.6–7.7)
ystolic 130 mm Hg and diastolic 85 mm Hg 1.94 (0.9–3.9)
lucose 110 mg/dl 1.95 (0.9–4.5)
G 150 mg/dl 2.08 (1.0–4.3)
DL 50 mg/dl 1.70 (0.8–3.7)
MI 25 kg/m2 1.78 (0.8–3.8)
RP values shown as median (interquartile range). For the gender analyses, females ei
omen on or off HRT is compared.
BMI  body mass index; CRP  C-reactive protein; HDL  high-density lipoproteinour months suggested an interaction between increasing
DL and glucose (PI  0.034) on the CRP level (Fig. 3).
imilarly, a statistically significant interaction was observed
etween high TG and low HDL on CRP level (PI 
.006). Statistically significant interactions for other com-
inations of risk factors (glucose, LDL, TG, and HDL) and
RP level were not observed.
5% confidence interval (CI) (log scale, y axis) across a range of metabolic
rsus glucose (mg/dl), (B) versus triglycerides (TG) (mg/dl), (C) versus
versus systolic blood pressure (mm Hg), (F) versus diastolic blood pressure
tion.
Risk Factors (Both Arms Combined), and a Comparison of
atients (B) Risk Factor Present
Factor
bsent p
Standard
Therapy
Intensive
Therapy p
(0.7–3.6) 0.14 2.07 (1.0–4.5) 1.42 (0.7–3.1) 0.0001
(0.7–3.2) 0.0001 2.49 (1.1–5.7) 1.71 (0.8–3.5) 0.0001
(0.7–3.5) 0.0002 2.69 (1.2–5.1) 1.49 (0.7–3.4) 0.0001
(0.7–3.1) 0.0001 2.85 (1.4–5.9) 1.93 (0.9–4.5) 0.0003
(0.7–3.1) 0.0001 4.30 (2.1–9.3) 2.73 (1.1–6.8) 0.015
(0.7–3.6) 0.025 2.59 (1.1–4.7) 1.34 (0.7–3.0) 0.0001
(0.7–3.3) 0.0001 2.89 (1.2–6.0) 1.44 (0.7–3.1) 0.0001
(0.7–3.2) 0.0001 2.32 (1.1–4.8) 1.67 (0.8–3.4) 0.0001
(0.7–3.6) 0.13 2.15 (1.0–4.5) 1.33 (0.7–3.0) 0.0001
(0.6–2.8) 0.0001 2.23 (1.1–4.7) 1.40 (0.7–3.0) 0.0001
n or off HRT is compared vs. males (A). In part B the effect of statin regimen amongand 9
A) veidual
s
All P
Risk
A
1.65
1.45
1.60
1.49
1.49
1.62
1.58
1.45
1.52
1.19
ther o; HRT  hormone replacement therapy; TG  triglycerides.
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October 18, 2005:1417–24 CRP, Risk Factors, and Intensive Statin Therapyodifiable risk factor control and achieved CRP level. Fi-
ally, the relationship between the number of persistent
ncontrolled risk factors present and CRP level was assessed
or each statin regimen. Presence or absence of each risk
actor was defined using existing established targets (BMI
25 kg/m2, TG 150 mg/dl, HDL 50 mg/dl, BP
130/85 mm Hg, glucose 110 mg/dl, LDL 70 mg/dl,
urrent smokers). The relationship between the number of
ncontrolled risk factors present and CRP level is graphi-
ally represented in Figure 4. Among patients allocated to
tandard therapy, CRP level was 3.8 mg/l (IQR, 1.9 to 7.8)
hen six to seven uncontrolled risk factors were present and
.0 mg/l (IQR, 0.7 to 2.1) when none were present, p 
.0001 for difference across the groups. In patients allocated
o intensive therapy, the corresponding CRP levels were
ower and ranged from 2.4 mg/l (IQR, 1.7 to 5.7) to 0.8
g/l (IQR, 0.4 to 1.2), p  0.0001 for difference across the
roups. Even when restricting the analysis to patients who
igure 2. The correlation between median C-reactive protein (CRP) level
nd 95% confidence interval (CI) (log scale, y axis) is shown using a Loess
lot against low-density lipoprotein (LDL) (mg/dl) for intensive and
tandard statin therapy.
Table 3. Multivariate Model of Independent P
All Patients
Intercept
Age (baseline)
Female on HRT (month 4) vs. male
Female not on HRT (month 4) vs. male
Current smoker (baseline)
BMI 25 kg/m2 (baseline)
HDLC 50 mg/dl (month 4)
LDL 70 mg/dl (month 4)
Glucose 110 mg/dl (month 4)
Clinical event pre-month 4
TG 150 mg/dl (month 4)
Atorvastatin 80 mg
Baseline diabetes, systolic blood pressure 130 mm Hg
clopidogrel, angiotensin-converting enzyme inhibitor, and g
statistical significance. *The effect of each risk factor on CRP
for log(CRP); e.g. atorvastatin 80 mg is associated with a CR
is 27.2% lower.BMI  body mass index; CI  confidence interval; CRP 
cholesterol; HRT  hormone replacement therapy; LDL  low-dchieved the LDL target of 70 mg/dl (n  1,113) (Fig.
A), or those who did not (LDL 70 mg/dl, n  1,772)
Fig. 5B), the relationship of increasing number of uncon-
rolled risk factors present and a higher CRP level was still
vident. In addition, there continued to be an advantage for
ntensive statin therapy over standard therapy across all
evels of overall risk factor burden. Additionally, patients
efined by the presence or absence of the metabolic syn-
rome had lower CRP levels on intensive therapy (p 
.0001 for each) (Table 4).
ISCUSSION
tatin therapy lowers CRP levels (9), and a recent analysis
as suggested that achieving a lower CRP level with statin
herapy in patients with ACS is associated with a lower rate
f recurrent cardiovascular events and less progression of
therosclerotic plaques (3,5). Despite the use of intensive
tatin therapy, CRP levels remain high in some patients (6).
herefore, consideration of how to lower the CRP levels
urther in this patient population beyond the use of statin
herapy requires an understanding of which factors could
otentially influence CRP levels. The present analysis shows
hat a more intensive statin regimen consistently achieved
ower CRP levels at four months, as compared with patients
andomized to standard-dose statin therapy independent of
ipid levels and the presence of uncontrolled cardiovascular
isk factors. However, even among patients receiving inten-
ive statin therapy, CRP levels vary widely, ranging from 0.8
g/l to 2.4 mg/l. In addition to the intensity of the statin
egimen, we observed that the presence of a number of
otentially modifiable cardiovascular risk factors such as
MI 25 kg/m2 and smoking, and to a lesser extent, LDL
70 mg/dl, glucose 110 mg/dl, HDL 50 mg/dl, and
G 150 mg/dl, were independently associated with
igher CRP levels (Table 3).
In apparently healthy and statin naive populations, the
resence of individual metabolic or coronary risk factors is
tors of Log (CRP)
(est)* 95% CI p
465 (0.31–0.69) 0.0001
012 (1.01–1.02) 0.0001
372 (1.97–2.85) 0.0001
470 (1.31–1.65) 0.0001
451 (1.32–1.59) 0.0001
420 (1.27–1.58) 0.0001
230 (1.11–1.36) 0.0001
198 (1.09–1.32) 0.0003
194 (1.08–1.33) 0.0009
354 (1.11–1.65) 0.0027
146 (1.05–1.25) 0.003
728 (0.66–0.8) 0.0001
astolic blood pressure 85 mm Hg (4 months), aspirin,
acin were also included in the model but did not achieve
ntified using the exponential of the estimate from the model
el of 0.728 times that of patients on pravastatin 40 mg, thatredic
Exp
0.
1.
2.
1.
1.
1.
1.
1.
1.
1.
1.
0.
and di
atiflox
is qua
P levC-reactive protein; HDLC  high-density lipoprotein
ensity lipoprotein; TG  triglycerides.
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CRP, Risk Factors, and Intensive Statin Therapy October 18, 2005:1417–24ssociated with a higher CRP level (10–12). In addition,
igher CRP levels have been observed, with an increase in
he number of components of the metabolic syndrome in
ealthy statin-naive populations (13). In the present analysis
f ACS patients in which all subjects received statin
herapy, the highest CRP levels were similarly observed
mong patients who had the greatest number of uncon-
rolled metabolic and/or lifestyle risk factors present. On
verage, a 0.3 to 0.5 mg/l higher CRP level was observed
ith each risk factor that was present (Fig. 4). Conversely,
he lower the number of risk factors present (i.e., BMI 25
g/m2, HDL 50 mg/dl, TG 150 mg/dl, glucose 110
g/dl, BP 130/85 mm Hg, LDL 70 mg/dl, and
bstinence from smoking), the lower the CRP level. Irre-
pective of the presence of a given risk factor (Table 2, part
) or cumulative risk factor burden (Fig. 4), randomization
o intensive versus standard statin therapy was associated
ith an approximately 1 mg/l lower CRP level. Thus, the
Figure 3. The interaction between quartiles of low-density lipoprotein (LD
igure 4. The relationship between the number of uncontrolled risk factors
resent and the median C-reactive protein (CRP) level for standard and
ntensive therapy. Risk factors were defined as body mass index (BMI)25
g/m2, triglycerides 150 mg/dl, high-density lipoprotein (HDL) 50
g/dl, glucose 110 mg/dl, blood pressure (BP) 130/85 mm Hg,m
ow-density lipoprotein (LDL) 70 mg/dl, current smoker. p  0.0001
cross the range of risk factors for each statin regimen.se of intensive statin therapy is associated with a signifi-
antly lower CRP level, independent of a patient’s cardio-
ascular risk factor profile.
Our observation of significant associations between the
resence of several uncontrolled risk factors and higher CRP
evels, even among intensively treated patients, identifies these
actors as important correlates of CRP in this population. We
lso observed statistically significant interactions between com-
inations of risk factors (specifically glucose and LDL and
etween TG and HDL) and a higher CRP level, suggesting
hat the relationship between the presence of multiple risk
actors and a higher CRP level may extend beyond simply
dditive risk factor burden alone. Adverse biological interac-
ions between risk factors such as glucose and LDL have been
bserved in vitro (14). The present data suggest that CRP
evels could be a useful method of monitoring such interactions
n vivo, beyond any additive effect. In trials of stable patients
ith risk factors, individual interventions such as use of
hiazolidinediones (15,16), fibrates (17,18), ezetimibe (19),
ndocannabinoid receptor blockers (20,21), increased exercise
22,23), weight loss (24–28), a Mediterranean diet (29),
ntensive glycemic control (30), and smoking cessation (31)
ave reported significant lowering of CRP levels. Therefore, in
CS patients, beyond the use of intensive statin therapy,
nterventions that control for these clinical risk factors may be
n important means of achieving a further reduction in CRP
evel.
The observed correlations between CRP level and the
resence of cardiovascular risk factors or use of different
ardioprotective regimens suggest that the CRP level could be
onsidered a useful “global barometer” of an individual’s
ardiovascular risk profile, and potentially of the effectiveness of
nterventions that modify known cardiovascular risk factors.
hus, as has been proposed, CRP levels may be a useful single
est to help titrate or monitor the effectiveness of lifestyle
hange or risk factor intervention in future clinical trials of
atients with CAD (32). This could be particularly useful in a
glucose on C-reactive protein (CRP) levels (intensive statin therapy arm).ulti-factorial approach to managing ACS patients for the
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for each statin regimen.
defined (on treatment) at 4 months, as the presence of 3 or more of the f
150 mg/dl, high-density lipoprotein 50 mg/dl, glucose 110 mg/
1423JACC Vol. 46, No. 8, 2005 Ray et al.
October 18, 2005:1417–24 CRP, Risk Factors, and Intensive Statin Therapyonitoring of lifestyle changes such as the amount of exercise,
ietary modification, or degree of weight loss, for which clear
argets are perhaps less well established.
Beyond seeing the change in CRP level, it is important to
nderstand the exact mechanisms by which different drugs or
nterventions modify the CRP level. In our analysis, high-dose
tatin therapy was associated with a lower CRP, even among
atients with an LDL that has achieved target level (70
g/dl) (Fig. 5A) and that could not be explained by adjusting
or known clinical correlates. This “gap” in the CRP level
etween standard and intensive statin therapy, which remained
ven after adjusting for risk factor burden, may have been
elated to greater pleiotropic effects related to statin dose, e.g.,
n the Rho/Rho kinase pathways (33), effects on lipid rafts
34), greater endothelial nitric oxide synthase generation (35),
r cytokine switching in T lymphocytes (immune modulation)
36), which were not directly measured but which could
ontribute to a reduction in inflammation. Further mechanistic
tudies are warranted to pinpoint the exact mechanisms by
hich different interventions reduce inflammation.
Although the relationship of CRP to LDL is weak, there is
small component of CRP that was associated with achieved
DL. Thus, some component of the reduction in CRP by
ntensive statin therapy seems to be attributable to the very low
DL levels achieved. With respect to this relationship, some
ifferences were observed (Figs. 2 and 5) between standard and
ntensive therapy that deserve further exploration. Further
tudy of these issues using different doses of the same statin and
ifferent statins at equivalent LDL-lowering doses could help
lucidate the relationship between LDL and CRP.
tudy limitations. This analysis is post hoc, and therefore
here are important limitations in interpretation. This anal-
sis was cross-sectional in design and did not assess the
ffect of specific interventions other than statin regimen.
ecause levels of metabolic markers during ACS do not
eflect true basal levels, we cannot comment on the possible
orrelation or lack of correlation between changes in these
arkers and changes in CRP in this analysis. In combined
nalyses of men and women, any HDL cut point would
ave been arbitrary. The mean HDL at four months was 43
g/dl, and so we deliberately used a higher HDL cut point
f 50 mg/dl, which approximated the inflection point on the
oess plot and is also the ATP III cut point in women (Fig.
). Similar results were obtained using an HDL level of 40
g/dl. Despite these limitations, this analysis is the most
obust observation yet that shows that the lower CRP level
CRP Levels in Patients With and Without
dard Therapy Intensive Therapy p
6 (0.9, 4.07) 1.13 (0.55, 2.73) 0.0001
(n  941) (n  1,060)
9 (1.22, 5.29) 1.59 (0.77, 3.33) 0.0001
(n  808) (n  698)
own in mg/l. Note the presence of the metabolic syndrome was
2igure 5. (A) The relationship between the number of uncontrolled risk
actors present and median C-reactive protein (CRP) level for standard and
ntensive therapy in patients with low-density lipoprotein (LDL) 70 mg/dl.
cross the range of risk factors, p  0.0001 for atorvastatin 80 mg and p 
.002 for pravastatin 40 mg. (B) The relationship between the number of
ncontrolled risk factors present and median CRP for standard and intensive
herapy in patients with LDL 70 mg/dl. Risk factors at target were defined
s body mass index (BMI)25 kg/m2, triglycerides150 mg/dl, high-density
ipoprotein (HDL) 50 mg/dl, glucose 110 mg/dl, blood pressure (BP)
130/85 mm Hg, current smoker. p 0.0001 across the range of risk factorsTable 4. Relationship Between Statin Regimen and
the Metabolic Syndrome
Stan
Absence of metabolic syndrome (0–2 risk factors) 1.7
Presence of metabolic syndrome (3–5 risk factors) 2.5
C-reactive protein (CRP) levels (median and interquartile range) are sh
ollowing risk factors (body mass index25 kg/m , triglycerides
dl, blood pressure 130/85 mm Hg).
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any subgroups and analyses.
ONCLUSIONS
mong patients receiving a statin as secondary prevention
fter ACS, randomization to high-dose statin therapy was
ndependently associated with a significantly lower CRP
evel irrespective of the number or type of risk factors
resent. Beyond intensity of statin therapy, control of risk
actors may be a further means of achieving a lower CRP
evel in ACS patients. In view of the observed correlations
etween CRP and modifiable cardiovascular risk factors or
ardioprotective regimens, the CRP level could be a useful
global barometer” of the effectiveness of lifestyle and
herapeutic interventions that modify cardiovascular risk.
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